CD19 and acute lymphoblastic leukemia: In addition to blinatumomab, CD19-targeted Chimeric Antigen Receptor T-Cell (CAR-T) therapies have been developed to treat BCP-ALL, leading to an improved OS and prolonged RFS [101,102,103,104,105].